The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-22. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
First, the surfactant molecules adsorb between the surface layer and the subsurface layer. Second, the molecules exchange between the subsurface and the bulk solution. Third, the micelles relax, caused by the breaking of equilibrium between free molecules and micelles. The molecules making up each micelle are organized depending on the solution they are suspended in, with the more soluble portions in contact with the solution, and the less soluble portions of the molecule in contact with each other. Depending on the ratio of volume of the polar heads and nonpolar tail, various surfactants have been found to form larger aggregates, hollow, bi-layered structures known as vesicles. A notable surfactant that has been witnessed to form vesicles is AOT (Dioctyl sulfosuccinate sodium salt). These micelles and vesicles are relatively new discoveries; however, they have been utilized to transport agents within microfluidic systems, revealing future applications for microfluidic transports.
The process required pressing tungsten powder into bars, then several steps of sintering, swaging, and then wire drawing. It was found that very pure tungsten formed filaments that sagged in use, and that a very small "doping" treatment with potassium, silicon, and aluminum oxides at the level of a few hundred parts per million (so-called AKS tungsten) greatly improved the life and durability of the tungsten filaments. The predominant mechanism for failure in tungsten filaments even now is grain boundary sliding accommodated by diffusional creep. During operation, the tungsten wire is stressed under the load of its own weight and because of the diffusion that can occur at high temperatures, grains begin to rotate and slide. This stress, because of variations in the filament, causes the filament to sag nonuniformly, which ultimately introduces further torque on the filament. It is this sagging that inevitably results in a rupture of the filament, rendering the incandescent lightbulb useless.
== Occurrence and applications == Many carboxylic acids are produced industrially on a large scale. They are also frequently found in nature. Esters of fatty acids are the main components of lipids and polyamides of aminocarboxylic acids are the main components of proteins. Carboxylic acids are used in the production of polymers, pharmaceuticals, solvents, and food additives. Industrially important carboxylic acids include acetic acid (component of vinegar, precursor to solvents and coatings), acrylic and methacrylic acids (precursors to polymers, adhesives), adipic acid (polymers), citric acid (a flavor and preservative in food and beverages), ethylenediaminetetraacetic acid (chelating agent), fatty acids (coatings), maleic acid (polymers), propionic acid (food preservative), terephthalic acid (polymers). Important carboxylate salts are soaps.
Sources: en.wikipedia.org
=== Medications === Certain medications increase the risk of hyperglycemia, including: corticosteroids, octreotide, beta blockers, epinephrine, thiazide diuretics, niacin, pentamidine, protease inhibitors, L-asparaginase, statins and antipsychotics. The administration of amphetamines initially produces hyperglycemia but later produces hypoglycemia. Thiazides are used to treat hypertension in type 2 diabetes but also may cause hyperglycemia.
== Biological role == DAO is involved in the physiology of digestion and other physiological processes, such as inflammation, immune response, and wound healing. Dysfunction of DAO has been associated with various diseases, including allergies, autoimmune disorders, and cancer. DAO also plays a role in healthy pregnancy in placental mammals. In case of a shortage or low enzymatic activity of diamine oxidase in the human body, it may appear as an allergy or histamine intolerance.
=== Inert gas condensation === Inert-gas condensation is frequently used to produce metallic nanoparticles. The metal is evaporated in a vacuum chamber containing a reduced atmosphere of an inert gas. Condensation of the supersaturated metal vapor results in creation of nanometer-size particles, which can be entrained in the inert gas stream and deposited on a substrate or studied in situ. Early studies were based on thermal evaporation. Using magnetron sputtering to create the metal vapor allows to achieve higher yields. The method can easily be generalized to alloy nanoparticles by choosing appropriate metallic targets. The use of sequential growth schemes, where the particles travel through a second metallic vapor, results in growth of core-shell (CS) structures.
Arias was elected president in 1968 following a populist campaign. Soon after taking office he launched a purge of the National Guard, sending much of its general staff into "diplomatic exile" or retirement. In response, Torrijos and a few other officers led a coup against him, ousting him after an eleven-day presidency. The coup was set in motion by Martínez, as the leader of the garrison at Chiriquí, and received the support of most military officers. A power struggle followed between the various forces involved in the coup, and chiefly between Torrijos and Martínez. Noriega was an important supporter of Torrijos during this conflict. In February 1969, Torrijos's men seized Martínez and exiled him to Miami giving Torrijos control of the country. At the end of 1969, Torrijos went to Mexico on holiday. A coup was launched in his absence, in which Noriega's loyalty allowed Torrijos to hang on to power, greatly enhancing Torrijos's image. Noriega was promoted to captain a month after the coup attempt: just 18 months later, in August 1970, Torrijos promoted him to the position of lieutenant colonel and appointed him chief of military intelligence. According to Dinges, by this point Noriega had left his undisciplined past behind him. When Arias's supporters launched a guerrilla uprising in his home province, Noriega as the head of intelligence played an important role in putting it down within a year. Torrijos retained power as a military ruler until 1981: during this time he negotiated the Torrijos–Carter Treaties with U.S.
Sources: en.wikipedia.org
==== Congenital fiber type disproportion ==== Congenital fiber type disproportion affects skeletal muscle, typically causing weakness in the shoulders, upper arms, thighs, and hips. Skeletal muscle is made up of two kinds of fiber, type 1 and type 2. In congenital fiber type disproportion, type 1 fibers are not only smaller but often more abundant than type 2 fibers. This leads to affected individuals being able to maintain an active lifestyle, though they usually have lower levels of stamina. Severity with this disease varies greatly, but people typically present symptoms by the age of one. Individuals do not usually worsen with time, and cases have even been reported of improvements.
April 1973: The Movement for the Freedom of Abortion and Contraception (MLAC) is created; it includes feminist and political organizations and announces the practice of then-illegal abortions (Karman method) and group trips abroad for abortion. July 11, 1973: Creation of the Higher Council for Sexual Information, Birth Control, and Family Education. October 8, 1973: Ministerial order extending national agreements concluded in the metallurgy sector; part of it concerns maternity leave compensation. May 1974: Simone Veil becomes Minister of Health; five other women serve as Secretaries of State between 1974 and 1976. July 16, 1974: Creation of the back-to-school allowance. July 23, 1974: The State Secretariat for the Status of Women is created; attached to the Prime Minister, it is assigned to Françoise Giroud. December 4, 1974: Law with various provisions regarding birth control. January 17, 1975: Law of January 17, 1975 on voluntary termination of pregnancy (abortion), also called the "Veil Law," which decriminalizes abortion; adopted for a five-year trial period. Its implementing decree was published on May 13, 1975, providing further details. July 10, 1975: Law amending Article 7 of Ordinance 59-244 of February 4, 1959 (no distinction is made between men and women for the application of this ordinance, except in certain cases where exclusive recruitment of men or women may be planned). July 11, 1975: Law reforming divorce.
=== Applications in marketing and advertising === Industry standards now cover AI agents that plan, negotiate, and buy digital media. In 2026, the technology arm of the Interactive Advertising Bureau, IAB Tech Lab, published the Agentic Advertising Management Protocols (AAMP), an open framework for agents that discover inventory, negotiate, and complete media transactions on behalf of buyers and sellers. This differs from platform-native automation such as Google Ads Smart Bidding and Meta Advantage+, which optimize bids and delivery inside a single advertising platform. Cross-channel agents instead recommend budget changes across media, typically with a human in the loop.
== Function == The endogenous system of opioid receptors is well known for its analgesic potential; however, the exact role of δ-opioid receptor activation in pain modulation is largely up for debate. This also depends on the model at hand since receptor activity is known to change from species to species. Activation of delta receptors produces analgesia, perhaps as significant potentiators of μ-opioid receptor agonists. However, it seems like delta agonism provides heavy potentiation to any mu agonism. Therefore, even selective mu agonists can cause analgesia under the right conditions, whereas under others can cause none whatsoever. It is also suggested however that the pain modulated by the μ-opioid receptor and that modulated by the δ-opioid receptor are distinct types, with the assertion that DOR modulates the nociception of chronic pain, while MOR modulates acute pain. Evidence for whether delta agonists produce respiratory depression is mixed; high doses of the delta agonist peptide DPDPE produced respiratory depression in sheep. In contrast both the peptide delta agonist Deltorphin II and the non-peptide delta agonist (+)-BW373U86 actually stimulated respiratory function and blocked the respiratory depressant effect of the potent μ-opioid agonist alfentanil, without affecting pain relief.
==== Parkinson's disease ==== Parkinson's disease may be due to mitochondrial dysfunction or oxidative stress, both of which could be caused by a decrease in glutathione levels. Administration of N-acetylcysteine has been shown to counter age-related damage to mitochondria. The therapeutic effects of N-acetylcysteine in the treatment of Parkinson's disease has not been examined yet, though there is a clinical trial that is currently ongoing.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.